The discovery of aspirin's antithrombotic effects

Texas Heart Institute Journal

Volumn 34, Issue 2, 2007, Pages 179-186

  Miner, Jonathan ^a,b   Hoffhines, Adam ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Aspirin history pharmacology therapeutic use; Bleeding time; Blood coagulation drug effects; History of medicine, 19th cent; History of medicine, 20th cent; Intracranial embolism and thrombosis prevention control; Lawrence Craven

Indexed keywords

ACETYLSALICYLIC ACID;

ANTICOAGULATION; CLINICAL TRIAL; DRUG EFFECT; GENERAL PRACTITIONER; HEART INFARCTION; HUMAN; LOW DRUG DOSE; REVIEW; STROKE;

ANIMALS; ASPIRIN; AWARDS AND PRIZES; CALIFORNIA; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HISTORY, 18TH CENTURY; HISTORY, 19TH CENTURY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS;

EID: 34447512883     PISSN: 07302347     EISSN: 15266702     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Jack DB. One hundred years of aspirin. Lancet 1997;350:437-9.
2. Stone E. An account of the success of the bark of the willow tree in the cure of agues. Philos Trans R Soc Lond 1763;53:195-200.
3. Leroux H. Discovery of salicine. J Chim Med 1830;6:340-432.
4. Hawkey CJ. COX-2 chronology. Gut 2005;54:1509-14.
5. MacLagan T. The treatment of acute rheumatism by salicin and salicylic acid. Lancet 1876;1:342-4.
6. Askwith R. How aspirin turned hero. Sunday Times [London]. 1998 Sep 13.
7. Dreser H. Pharmakologisches uber aspirin (acetylsalicylsaure). Pflugers Arch 1899;76:306-18.
8. Weiss HJ. The discovery of the antiplatelet effect of aspirin: a personal reminiscence [published erratum appears in J Thromb Haemost 2003;1:2266]. J Thromb Haemost 2003;1:1869-75.
9. Master AM, Jaffe HL. Factors in the onset of coronary occlusion and coronary insufficiency; effort, occupation, trauma and emotion. J Am Med Assoc 1952;148:794-8.
10. Plotz M. The preventive aspects of coronary disease and myocardial infarction. N Y State J Med 1944;4:1227-9.
11. Dr. Lawrence Craven, Glendale physician, dies. Los Angeles Times. 1957 Aug 19;5.
12. Times asst. editor Earl Craven dies. Los Angeles Times. 1956 Jan 9;A1.
13. Barton WS. Glendale physician wins award for heart paper. Los Angeles Times. 1952 Oct 3;A3.
14. Dalen JE. An apple a day or an aspirin a day? Arch Intern Med 1991;151:1066-9.
15. Craven LL. Acetylsalicylic acid: possible preventive of coronary thrombosis. Ann West Med Surg 1950;4:95-9.
16. Govan CD. The effect of salicylate administration on prothrombin time. J Pediatr 1946;29:629-36.
17. Singer R. Acetylsalicylic acid, a probable cause for secondary post-tonsillectomy hemorrhage. Arch Otolaryngol 1945;42:19-20.
18. Rapp G. Cause of delayed hemorrhage after tooth extraction. J Am Dent Assoc 1947;34:484.
19. Craven LL. Coronary thrombosis can be prevented. J Insur Med 1950;5:47-8.
20. Craven LL. Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Miss Valley Med J 1953;75:38-44.
21. Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1956;78:213-5.
22. Solley RF, Griffith GC, Huntington RW, Montgomery H. Studies in rheumatic fever. I. The physiologic effect of sodium salicylate on the human being, with particular reference to the prothrombin level of the blood and the effect on hepatic parenchyma. J Amer Med Assoc 1945;128:1195-200.
23. Coombs FS, Higley CS, Warren HA. The magnitude of salicylate hypoprothrombinemia. Proc Am Fed Clin Res 1945;2:57-8.
24. Clausen FW, Jager BV. The relation of the plasma salicylate level to the degree of hypoprothrombinemia. J Lab Clin Med 1946;31:428-36.
25. McEver RP, Cummings RD. Perspectives series: cell adhesion in vascular biology. Role of PSGL-1 binding to selectins in leukocyte recruitment. J Clin Invest 1997;100:485-91.
26. Ruggeri ZM. von Willebrand factor [published erratum appears in J Clin Invest 1997;100:237]. J Clin Invest 1997;99:559-64.
27. Ruggeri ZM. Mechanisms initiating platelet thrombus formation [published erratum appears in Thromb Haemost 1997;78:1304]. Thromb Haemost 1997;78:611-6.
28. Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002;8:1227-34.
29. Quick AJ. Salicylates and bleeding: the aspirin tolerance test. Am J Med Sci 1966;252:265-9.
30. Weiss HJ, Aledort LM. Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 1967;2:495-7.
31. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest 1968;47:2169-80.
32. Weiss HJ, Tschopp TB, Baumgartner HR. Impaired interaction (adhesion-aggregation) of platelets with the subendothelium in storage-pool disease and after aspirin ingestion. A comparison with von Willebrand's disease. N Engl J Med 1975;293:619-23.
33. O'Brien JR. Effect of salicylates on human platelets. Lancet 1968;1:1431.
34. Mustard JF, Glynn MF, Nishizawa EE, Packham MA. Platelet-surface interactions: relationship to thrombosis and hemostasis. Fed Proc 1967;26:106-14.
35. Packham MA, Warrior ES, Glynn MF, Senyi AS, Mustard JF. Alteration of the response of platelets to surface stimuli by pyrazole compounds. J Exp Med 1967;126:171-88.
36. Evans G, Packham MA, Nishizawa EE, Mustard JF, Murphy EA. The effect of acetylsalicyclic acid on platelet function. J Exp Med 1968;128:877-94.
37. al-Mondhiry H, Marcus AJ, Spaet TH. On the mechanism of platelet function inhibition by acetylsalicylic acid. Proc Soc Exp Biol Med 1970;133:632-6.
38. Vane JR. The use of isolated organs for detecting active substances in the circulating blood. Br J Pharmacol Chemother 1964;23:360-73.
39. Vane JR. Adventures and excursions in bioassay: the stepping stones to prostacylin. Biosci Rep 2004;24:254-79.
40. Piper PJ, Vane JR. The release of prostaglandins during anaphylaxis in guinea-pig isolated lungs. In: Mantegazza P, Hor ton EW, editors. Prostaglandins, peptides, and amines. London: Academic Press; 1969. p. 15-9.
41. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231:232-5.
42. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 1975;72:2994-8.
43. Smith JB, Willis AL. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol 1971;231:235-7.
44. Roth GJ, Stanford N, Majerus PW. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 1975;72:3073-6.
45. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published erratum appears in BMJ 2002;324:141]. BMJ 2002;324:71-86.
46. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321:129-35.
47. Dalen JE. Aspirin to prevent heart attack and stroke: what's the right dose? Am J Med 2006;119:198-202.